Results 181 to 190 of about 101,002 (279)

Pemafibrate, a novel selective peroxisome proliferator-activated receptor alpha modulator, improves the pathogenesis in a rodent model of nonalcoholic steatohepatitis [PDF]

, 2017
Yasushi Honda, Takaomi Kessoku, Yuji Ogawa, Wataru Tomeno, Kento Imajo, Koji Fujita, Masato Yoneda, Toshiaki Takizawa, Satoru Saito, Yoji Nagashima, Atsushi Nakajima   +10 more
openalex   +1 more source

Akkermansia muciniphila suppressing nonalcoholic steatohepatitis associated tumorigenesis through CXCR6+ natural killer T cells

, 2022
Tao Li, Xinlong Lin, Binhai Shen, Wujian Zhang, Yang Liu, Hongbin Liu, Ye Wang, Lijun Zheng, Fachao Zhi   +8 more
openalex   +1 more source

Fat‐Corrected Non‐Gaussian Diffusion MRI for Liver Fibrosis Assessment in Metabolic Dysfunction‐Associated Steatotic Liver Disease

Journal of Magnetic Resonance Imaging, Volume 63, Issue 2, Page 497-507, February 2026.
ABSTRACT Background In patients with metabolic dysfunction‐associated steatotic liver disease (MASLD), non‐Gaussian diffusion—weighted imaging (DWI) has been proposed for the diagnosis of liver fibrosis, but its measurement is partially confounded by steatosis.
Omaïma Saïd, Sabrina Doblas, Valérie Paradis, Pierre Bedossa, Dominique Valla, Cédric Laouénan, Laurent Castera, Bernard E. Van Beers, Philippe Garteiser   +8 more
wiley   +1 more source

Plasma insulin, leptin, adiponectin, resistin, ghrelin, and melatonin in nonalcoholic steatohepatitis patients treated with melatonin

, 2012
Maciej Gonciarz, Władysław Bielański, Robert Partyka, Tomasz Brzozowski, P C Konturek, Jerzy Eszyk, Krzysztof Celiński, Rüssel J. Reiter, Stanisław J. Konturek   +8 more
openalex   +2 more sources

The Proteomic Profiling of Circulating Extracellular Vesicles of Western Diet and Chemical‐Induced Murine MASH Model

The Kaohsiung Journal of Medical Sciences, Volume 42, Issue 2, February 2026.
ABSTRACT Metabolic dysfunction‐associated steatotic liver disease (MASLD) is an increasingly prevalent chronic liver condition that can progress to severe complications such as metabolic dysfunction‐associated steatohepatitis (MASH). Despite its growing burden, there are no reliable non‐invasive biomarkers for tracking disease progression.
Szu‐Jen Wang, Yung‐Ho Wang, Jee‐Fu Huang, En‐Sheng Lin, Wei‐Shiun Chen, Chia‐Yang Li, Chia‐Yen Dai, Wan‐Long Chuang, Ming‐Lung Yu, Shu‐Chi Wang   +9 more
wiley   +1 more source

Histological Remission during Corticosteroid Therapy of Overlapping Nonalcoholic Steatohepatitis and Autoimmune Hepatitis: Case Report and Literature Review [PDF]

, 2011
Shinichiroh Fukuda, Atsumasa Komori, Masahiro Itoh, Yumi Mihara, Satoru Hashimoto, Sung Kwan Bae, Shinya Nagaoka, Seigo Abiru, Hiroshi Yatsuhashi, Hiromi Ishibashi   +9 more
openalex   +1 more source

Inflammation and Cancer: Molecular Mechanisms and Therapeutic Targets

MedComm, Volume 7, Issue 2, February 2026.
Chronic inflammation fuels tumorigenesis via “internal drivers” and “external attractions.” Targeting these core mechanisms with combined therapies/novel deliveries enables precise, potent anti‐inflammatory–antitumor treatment. ABSTRACT Inflammation is a core pathological factor regulating tumor initiation, progression, and therapeutic resistance, and ...
Xiaodie Liu, Ziyuan Wang, Huirong Zhu, Yicun Han, Qing Ji   +4 more
wiley   +1 more source

Model‐Based Meta‐Analysis of the Relationship Between Pioglitazone and Histological Outcomes in Metabolic Dysfunction‐Associated Steatohepatitis Patients

CPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 2, February 2026.
ABSTRACT Given the high prevalence of the population who have metabolic dysfunction‐associated steatohepatitis (MASH), interest is growing in MASH‐targeted treatments. However, currently, there has been only one regulatory approved drug for MASH (Rezdiffra).
Quyen Thi Tran, Tham Thi Bui, Lien Thi Ngo, Bo Ram Yang, In‐Hwan Baek, Van Hung Nguyen, Kyung Ae Lee, Hwi‐yeol Yun, Jung‐woo Chae, Soyoung Lee, Jae Hyun Kim, Woojin Jung   +11 more
wiley   +1 more source

Hevin Promotes Aging‐Related Cardiac Dysfunction via Facilitating Cardiac Inflammation in Male Mice

Aging Cell, Volume 25, Issue 2, February 2026.
Hevin released by iWAT into circulation stimulates cardiac macrophages through TLR4, inducing their polarization and CCL5 secretion, leading to worsened cardiac dysfunction and subsequent recruitment of additional inflammatory cells for pro‐inflammatory factor release.
Shi‐Yu Huang, Yu‐Jie Chen, Yu‐Xin Hu, Jia‐Chen Liu, Min Hu   +4 more
wiley   +1 more source

Exploration of Multiple Non‐Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients with MASH

Alimentary Pharmacology &Therapeutics, Volume 63, Issue 3, Page 396-404, February 2026.
This study investigated multiple non‐invasive tests (NIT) in a phase 2b study of patients with MASH and fibrosis treated with semaglutide. Findings revealed that semaglutide significantly improved NIT scores versus placebo from as early as 28 weeks. The results support the use of NITs to assess a treatment response to semaglutide.
Louise Maymann Nitze, Vlad Ratziu, Arun J. Sanyal, Vincent Wai‐Sun Wong, Clare Balendran, Jan Fleckner, Mette Skalshøi Kjær, Niels Krarup, Quentin M. Anstee   +8 more
wiley   +1 more source